Home / Reports

Reports

Generics market share in Europe

Generics make a major contribution to the European drug supply, according to a report by the by Germany-based Institute for Healthcare and Social Research (IGES).

Generics reduce costs and increase access

Generics reduce costs for both patients and payers and increase patient’s access to medicines, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).

Generics savings continue to climb in the US

Generics manufacturers have joined to celebrate the latest data from the Generic Drug Savings in the US report. According to the report, the US healthcare system saved a record US$254 billion in 2014 from generics, or US$1.68 trillion between 2005 and 2014.

Pivotal clinical trials for trastuzumab biosimilars

Biosimilars of Roche’s Herceptin (trastuzumab), a humanized monoclonal antibody are currently under development.

Pivotal clinical trials for rituximab biosimilars

Biosimilars of Roche’s MabThera/Rituxan (rituximab), a chimeric monoclonal antibody are currently under development.

German physicians not pressured to switch to biosimilar infliximab

Rheumatologists and gastroenterologists in Germany are not being put under pressure to switch patients from Remicade (infliximab) to biosimilar infliximab, according to a new report from research and advisory firm Decision Resources.

Pivotal clinical trials for bevacizumab biosimilars

Biosimilars of Roche’s Avastin (bevacizumab), a humanized monoclonal antibody, are currently under development.

Pivotal clinical trials for infliximab biosimilars

Biosimilars of Johnson & Johnson’s blockbuster arthritis drug Remicade (infliximab), a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-α), are currently under development.

Pivotal clinical trials for etanercept biosimilars

Biosimilars of Amgen/Pfizer’s blockbuster arthritis drug Enbrel (etanercept), a fusion protein produced by recombinant DNA, are currently under development.

Pivotal clinical trials for adalimumab biosimilars

Biosimilars of AbbVie’s Humira (adalimumab), a human monoclonal antibody, are currently under development.